2
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Genitourinary
2
Lymphoid
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Rituximab
1401
Cyclophosphamide
1306
Vincristine
668
Doxorubicin
587
Etoposide
527
Prednisone
511
Cytarabine
486
fludarabine
470
Methotrexate
445
Dexamethasone
413
fludarabine phosphate
400
Lenalidomide
356
Filgrastim
343
Bendamustine Hydrochloride
282
Radiotherapy
267
venetoclax
261
ibrutinib
258
obinutuzumab
236
Peripheral Blood Stem Cell Transplantation
234
Melphalan
230
Granulocyte Colony-Stimulating Factor
215
Bortezomib
204
Gemcitabine
202
Busulfan
188
Whole-Body Irradiation
187
Mycophenolic Acid
175
Tacrolimus
165
Specimen Handling
162
Magnetic Resonance Spectroscopy
155
Calcium Dobesilate
150
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inosine Monophosphate
×
Lymphoid
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled